Individuals who use heroin and illicit opioids are at high risk for infection with human immunodeficiency virus (HIV) and other blood-borne pathogens, as well as incarceration. The purpose of the randomized trial reported here is to compare outcomes between participants who initiated methadone maintenance treatment (MMT) prior to release from incarceration, with those who were referred to treatment at the time of release. Participants who initiated MMT prior to release were significantly more likely to enter treatment postrelease (P < .001) and for participants who did enter treatment, those who received MMT prerelease did so within fewer days (P = .03). They also reported less heroin use (P = .008), other opiate use (P = .09), and injection drug use (P = .06) at 6 months. Initiating MMT in the weeks prior to release from incarceration is a feasible and effective way to improve MMT access postrelease and to decrease relapse to opioid use.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278074PMC
http://dx.doi.org/10.1080/08897077.2011.609446DOI Listing

Publication Analysis

Top Keywords

prior release
16
release incarceration
12
randomized trial
8
participants initiated
8
mmt prior
8
enter treatment
8
release
5
mmt
5
trial methadone
4
methadone initiation
4

Similar Publications

Mediastinal mass syndrome represents a major threat to respiratory and cardiovascular integrity, with difficult evidence-based risk stratification for interdisciplinary management. We conducted a narrative review concerning risk stratification and difficult airway management of patients presenting with a large mediastinal mass. This is supplemented by a case report illustrating our individual approach for a patient presenting with a subtotal tracheal stenosis due to a large cyst of the thyroid gland.

View Article and Find Full Text PDF

Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists.

Cancer Treat Rev

January 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 Guangzhou, China; Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 Guangzhou, China. Electronic address:

Background: Ovarian function suppression (OFS) has emerged as a crucial adjuvant therapy for premenopausal breast cancer patients. Some patients fail to achieve complete OFS with commonly used OFS drugs. The definition of incomplete OFS remains unclear, and large-scale data on its incidence are lacking.

View Article and Find Full Text PDF

Radionuclide sorption dynamics in the Rhone River: Experimental and modelling approach.

J Environ Radioact

January 2025

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-ENV/STAAR/LRTA, PSE-ENV/SPDR/LT2S, Saint-Paul-lez-Durance, F-13115, France. Electronic address:

The transfer of radionuclides discharged into rivers by nuclear facilities are conditioned by their solid/liquid fractionation, commonly represented by an equilibrium approach using the distribution coefficient K. This coefficient, largely used in modeling, assumes an instantaneous and completely reversible reaction. However, such assumptions are rarely verified.

View Article and Find Full Text PDF

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.

View Article and Find Full Text PDF

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) effectively treat EGFR-mutant lung adenocarcinoma, demonstrating initial efficacy but eventually leading to acquired resistance. Small cell transformation is a rare resistance mechanism to EGFR-TKIs in lung adenocarcinoma, which can complicate clinical diagnosis and treatment. We present a patient with lung adenocarcinoma who underwent a prior pneumonectomy and adjuvant chemotherapy and was treated with osimertinib after the recurrence of lung cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!